ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
The characterization of RUNX1-mediated macrophage polarization requires a multidimensional perspective beyond the M1/M2 binary.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophages in oncoviral infections: from immune regulators to therapeutic targets.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- From description to prediction: a multi-database bibliometric forecast-validation study of lung cancer and tumor-associated macrophages research (2005-2025).Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We comment on the recent study by He et al. reporting that RUNX1 promotes non-small cell lung cancer (NSCLC) progression by driving a pro-tumoral macrophage program via the ACP5/β-catenin/SMAD3 axis, interpreted as "M2" polarization. While the M1/M2 framework (e.g., CD86 vs. CD206/Arg1) remains widely used, accumulating single-cell and spatial profiling data indicate that tumor-associated macrophages (TAMs) in vivo occupy a multidimensional continuum and may co-express canonical inflammatory and anti-inflammatory markers, challenging binary labeling. We propose that RUNX1 may induce a more specific TAM transcriptional program than a generic "M2" state and encourage future studies to apply high-resolution subtype annotations (e.g., SPP1 or C1QC TAM signatures) to define RUNX1-associated macrophage states more precisely. In addition, validating the RUNX1 axis in immunocompetent models (beyond NOD/SCID settings) and identifying tumor-derived upstream inducers (e.g., cytokines or exosomal cargos) would strengthen mechanistic completeness and translational relevance.
Indexed as
Identifiers
41843115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.